<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454115</url>
  </required_header>
  <id_info>
    <org_study_id>CN156-001</org_study_id>
    <nct_id>NCT01454115</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163</brief_title>
  <official_title>Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Subjects and a Comparison to Elderly Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety and tolerability of a single oral dose of
      BMS-708163 in healthy young male subjects and in elderly male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of Single doses of BMS-708163 in the range of 0.3 to 800 mg in the healthy subjects</measure>
    <time_frame>Within 28 days of dosing</time_frame>
    <description>Based on adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of BMS-708163 on cortisol and QT interval corrected for heart rate</measure>
    <time_frame>Within 28 days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of BMS-708163 on thyroid stimulating hormone (TSH), free triiodothyronine (T3), free thyroxine (T4), and lymphocyte subsets</measure>
    <time_frame>Within 28 days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of BMS-708163 from a capsule formulation relative to a solution formulation</measure>
    <time_frame>Within 28 days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on the PK of BMS-708163 administered as a capsule formulation</measure>
    <time_frame>Within 28 days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-708163</measure>
    <time_frame>Within 28 days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-708163</measure>
    <time_frame>Within 28 days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-708163</measure>
    <time_frame>Within 28 days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-708163</measure>
    <time_frame>Within 28 days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T-HALF) of BMS-708163</measure>
    <time_frame>Within 28 days of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Panel 1: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male subjects (age: 18 to 45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male subjects (age: 18 to 45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 3: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male subjects (age: 18 to 45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 4: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male subjects (age: 18 to 45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 5: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male subjects (age: 18 to 45 years).
In Period 2: Subjects will receive BMS-708163 or placebo as a capsule formulation.
In Period 3: Subjects will receive BMS-708163 or placebo as a capsule formulation within 5 minutes of consuming a standard high-fat breakfast on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 6: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male subjects (age: 18 to 45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 7: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male subjects (age: 18 to 45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 8: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male subjects (age: 18 to 45 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 9: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, elderly male subjects (age: 60 years and greater)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 10: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, elderly female subjects (age: 60 years and greater)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 11: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male subjects (age: between 46 to 59 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 12: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and/or female subjects or subjects with MCI (age: between 60-74 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 13: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy male and/or female subjects or with AD or MCI (age: 75 years or greater)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 15: BMS-708163 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy young male subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163 (Gamma-Secretase Inhibitor)</intervention_name>
    <description>Oral Solution, Oral, 0.3 mg, Once daily, once</description>
    <arm_group_label>Panel 1: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163 (Gamma-Secretase Inhibitor)</intervention_name>
    <description>Oral Solution, Oral, 1.5 mg, Once daily, once</description>
    <arm_group_label>Panel 2: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163 (Gamma-Secretase Inhibitor)</intervention_name>
    <description>Oral Solution, Oral, 5.0 mg, Once daily, once</description>
    <arm_group_label>Panel 3: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163 (Gamma-Secretase Inhibitor)</intervention_name>
    <description>Oral Solution, Oral, 15.0 mg, Once daily, once</description>
    <arm_group_label>Panel 4: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163 (Gamma-Secretase Inhibitor)</intervention_name>
    <description>Oral Solution, Oral, 50 mg, Once daily, once</description>
    <arm_group_label>Panel 5: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 9: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 10: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163 (Gamma-Secretase Inhibitor)</intervention_name>
    <description>Oral Solution, Oral, 100 mg, Once daily, once</description>
    <arm_group_label>Panel 6: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163 (Gamma-Secretase Inhibitor)</intervention_name>
    <description>Oral Solution, Oral, 200 mg, Once daily, once</description>
    <arm_group_label>Panel 7: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163 (Gamma-Secretase Inhibitor)</intervention_name>
    <description>Oral Solution, Oral, 400 mg, Once daily, once</description>
    <arm_group_label>Panel 8: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163 (Gamma-Secretase Inhibitor)</intervention_name>
    <description>Capsule, Oral, 50 mg, Once daily, once</description>
    <arm_group_label>Panel 5: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 11: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 12: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 13: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163 (Gamma-Secretase Inhibitor)</intervention_name>
    <description>Oral Solution, Oral, 800 mg, Once daily, once</description>
    <arm_group_label>Panel 15: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-708163</intervention_name>
    <description>Oral Solution, Oral, 0 mg, Once daily, once</description>
    <arm_group_label>Panel 1: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 2: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 3: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 4: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 5: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 6: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 7: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 8: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 9: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 10: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 15: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-708163</intervention_name>
    <description>Capsule, Oral, 0 mg, Once daily, once</description>
    <arm_group_label>Panel 5: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 11: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 12: BMS-708163 or Placebo</arm_group_label>
    <arm_group_label>Panel 13: BMS-708163 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Panels 1- 8 and Panels 14-15: healthy male subjects between the ages of 18 to 45

          -  Panels 9 and 10: healthy elderly males and females ages 60 and greater

          -  Panel 11: healthy males between the ages of 46-59

          -  Panel 12: males and/or females either healthy or with mild cognitive impairment (MCI)
             between the ages of 60 and 74

          -  Panel 13: males and/or females, healthy or with Alzheimer's disease (AD) or MCI that
             were 75 years of age or greater

          -  Acceptable medical history, physical examinations, vital signs, electrocardiograms,
             hemoccult stool tests, and clinical laboratory evaluations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2011</study_first_posted>
  <last_update_submitted>November 18, 2011</last_update_submitted>
  <last_update_submitted_qc>November 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

